Pastores S M, Hasko G, Vizi E S, Kvetan V
Department of Anesthesiology, Montefiore Medical Center/Albert Einstain College of Medicine, Bronx, NY 10467, USA.
New Horiz. 1996 May;4(2):252-64.
The management of severe sepsis includes the use of agonists of alpha- and beta-adrenergic, as well as of dopaminergic, receptors. Data suggest that the severe inflammatory immune response seen in sepsis can be modulated by stimulation and inhibition of these receptors both in vitro and in vivo. Specifically, release of tumor necrosis factor and interleukins can clearly be modified. Thus, pharmacologic agents directed at circulatory support may have significant potential for immunomodulation. Since the vasopressor and inotrope support of sepsis is not well standardized, variability in the resulting inflammatory mediator response may have consequences to the efficacy of new immunotherapies. This article provides an overview of the effect of the sympathetic nervous system activity and of receptor manipulation on cytokine response to endotoxin, and adds to the perspective on inhibition of phosphodiesterase in the therapy of septic shock.
严重脓毒症的治疗包括使用α-和β-肾上腺素能受体激动剂以及多巴胺能受体激动剂。数据表明,脓毒症中出现的严重炎症免疫反应在体外和体内均可通过刺激和抑制这些受体来调节。具体而言,肿瘤坏死因子和白细胞介素的释放可明显改变。因此,针对循环支持的药物制剂可能具有显著的免疫调节潜力。由于脓毒症的血管加压药和正性肌力药支持尚未得到很好的标准化,由此产生的炎症介质反应的变异性可能会影响新免疫疗法的疗效。本文概述了交感神经系统活动和受体操纵对内毒素细胞因子反应的影响,并增加了对脓毒性休克治疗中磷酸二酯酶抑制作用的认识。